-- 
Biotie Therapies Acquires Newron for 45 Million Euros

-- B y   K a t i   P o h j a n p a l o
-- 
2011-09-27T05:07:42Z

-- http://www.bloomberg.com/news/2011-09-27/biotie-therapies-acquires-newron-for-45-million-euros.html
Biotie Therapies Oyj (BTH1V)  will acquire
Newron Pharmaceuticals S.p.A. in a transaction valued at 45
million euros.  The company will have a “deep” pipeline with nalmefene
and safinamide in late-stage Phase 3 development targeting
alcohol dependence and Parkinson’s disease, the Turku, Finland-
based company said. Timo Veromaa will act as the Chief Executive
Officer of the merged company while Newron Managing Director
Luca Benatti will step down as the transaction is closed.  To contact the editor responsible for this story:
Kati Pohjanpalo at 
 kpohjanpalo@bloomberg.net  